Neurodyn Aussie Sport is electric current application equipment for applying electrical current via electrodes in direct contact with the patient. It is a transcutaneous neuromuscular stimulator which uses microcomputer technology, that is, it is controlled by a computer, and is operated by touch screen. All the information related to the parameters selected by the physiotherapist will be shown in the alphanumeric liquid crystal display.
Neurodyn Aussie Sport stimulator produces AUSSIE CURRENT (also called Australian Current), a “new generation” of electrical current for stimulation with some advantages on the traditional methods of stimulation (Russian, Interferential, TENS e FES). This technique is non-invasive, non-addictive, and without undesirable side effects.
Neurodyn Aussie Sport is electric current application equipment for applying electrical current via electrodes in direct contact with the patient. It is a transcutaneous neuromuscular stimulator which uses microcomputer technology, that is, it is controlled by a computer, and is operated by touch screen. All the information related to the parameters selected by the physiotherapist will be shown in the alphanumeric liquid crystal display.
Neurodyn Aussie Sport stimulator produces AUSSIE CURRENT (also called Australian Current), a “new generation” of electrical current for stimulation with some advantages on the traditional methods of stimulation (Russian, Interferential, TENS e FES). This technique is non-invasive, non-addictive, and without undesirable side effects.
ShuntCheck is an aid to the detection of flow in implanted cerebrospinal fluid (CSF) shunts. ShuntCheck includes Micro-Pumper, a component which may be used to temporarily increase CSF flow in suspected non-flowing, patent shunts during the ShuntCheck test. ShuntCheck cannot alone diagnose CSF shunt function or malfunction. The clinical diagnosis of CSF shunt function or malfunction, incorporating the flow information from ShuntCheck, should be made only by a qualified neurosurgeon.
Estimulación cardiaca sin cables
08/10/2015 13:30-15:00h Casa del Corazón, Madrid
http://marcapasossincables.secardiologia.es
#marcapasossincables
La estimulación sin cables: resultados a medio plazo
Dr. Lluís Mont Girbau, Hospital Clínic (Barcelona)
@Montgirbau
Neuro-Stim System Neurostim FDA K140530 Electro Acupuncture Devicemcalipo
Neuro-Stim Electro Acupuncture device and Electro Acupuncture Stimulator. The Electro Auricular Device or PENS (Percutaneous Electrical Nerve Stimulation). Neurostimulation pain therapy medical devices deliver a therapeutic electrical signal into auricular nerves to help release endorphins and provide pain relief.
https://www.laserspineinstitute.com/spinal_orthopedic_procedures/neurostim/
Hướng dẫn sử dụng đồng hồ vạn năng Testo 760
https://testostore.vn/san-pham/dong-ho-van-nang-so-testo-760-1/
https://testostore.vn/san-pham/dong-ho-van-nang-so-testo-760-2/
https://testostore.vn/san-pham/dong-ho-van-nang-testo-760-3/
https://testostore.vn/danh-muc/do-dien/dong-ho-van-nang/
Hướng dẫn sử dụng Testo 435
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
Hướng dẫn sử dụng máy đo nhiệt độ bề mặt Testo 435-3Tenmars Việt Nam
Hướng dẫn sử dụng máy đo nhiệt độ bề mặt Testo 435-3
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/san-pham/may-do-da-nang-testo-435-4/
https://testostore.vn/danh-muc/do-nhiet-do-do-am/do-nhiet-do-be-mat/
Hướng dẫn sử dụng testo 435-3
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
Hướng dẫn sử dụng Testo 435-3
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
ShuntCheck is an aid to the detection of flow in implanted cerebrospinal fluid (CSF) shunts. ShuntCheck includes Micro-Pumper, a component which may be used to temporarily increase CSF flow in suspected non-flowing, patent shunts during the ShuntCheck test. ShuntCheck cannot alone diagnose CSF shunt function or malfunction. The clinical diagnosis of CSF shunt function or malfunction, incorporating the flow information from ShuntCheck, should be made only by a qualified neurosurgeon.
Estimulación cardiaca sin cables
08/10/2015 13:30-15:00h Casa del Corazón, Madrid
http://marcapasossincables.secardiologia.es
#marcapasossincables
La estimulación sin cables: resultados a medio plazo
Dr. Lluís Mont Girbau, Hospital Clínic (Barcelona)
@Montgirbau
Neuro-Stim System Neurostim FDA K140530 Electro Acupuncture Devicemcalipo
Neuro-Stim Electro Acupuncture device and Electro Acupuncture Stimulator. The Electro Auricular Device or PENS (Percutaneous Electrical Nerve Stimulation). Neurostimulation pain therapy medical devices deliver a therapeutic electrical signal into auricular nerves to help release endorphins and provide pain relief.
https://www.laserspineinstitute.com/spinal_orthopedic_procedures/neurostim/
Hướng dẫn sử dụng đồng hồ vạn năng Testo 760
https://testostore.vn/san-pham/dong-ho-van-nang-so-testo-760-1/
https://testostore.vn/san-pham/dong-ho-van-nang-so-testo-760-2/
https://testostore.vn/san-pham/dong-ho-van-nang-testo-760-3/
https://testostore.vn/danh-muc/do-dien/dong-ho-van-nang/
Hướng dẫn sử dụng Testo 435
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
Hướng dẫn sử dụng máy đo nhiệt độ bề mặt Testo 435-3Tenmars Việt Nam
Hướng dẫn sử dụng máy đo nhiệt độ bề mặt Testo 435-3
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/san-pham/may-do-da-nang-testo-435-4/
https://testostore.vn/danh-muc/do-nhiet-do-do-am/do-nhiet-do-be-mat/
Hướng dẫn sử dụng testo 435-3
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
Hướng dẫn sử dụng Testo 435-3
https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
https://testostore.vn/danh-muc/do-ap-suat/may-do-ap-suat-vi-sai/
Hướng dẫn sử dụng máy đo đa năng Testo 435 đo nhiệt độ độ ẩm, đo áp suất, tốc độ gió...
Máy đo áp suất đa năng Testo 435: https://testostore.vn/san-pham/dong-ho-do-da-nang-testo-435-3/
Máy đo nhiệt độ bề mặt: https://testostore.vn/danh-muc/do-nhiet-do-do-am/do-nhiet-do-be-mat/
Website: testostore.vn
Hotline: 0914222214
Email: info@thietbido.us , info@tenmars.vn
This manual is written for the PC-200 Spot-Check Monitor.
The manual describes, in accordance with the Spot-Check Monitor’s features and requirements, the main
structure, functions, specifications, correct methods for transportation, installation, usage, operation,
repair, maintenance and storage, etc. as well as the safety procedures to protect both the user and
equipment. Refer to the respective chapters for further details.
The manual is published in English and Creative has the ultimate right to explain the Manual.
For the user's convenience, we provide the latest version of PC software for the Spot-Check Monitor,
which can be downloaded from our website (www.creative-sz.com). Please consult the manufacturer or
local distributor for any issue about the software downloading.
The smoke detector Z-Wave detects fire and smoke emissions. In case of emergency, it gives an audible alert and sends an alarm signal to the Z-Wave network
Schwinn 430 elliptical trainer User ManualEllipticalHUB
This is the User manual for Schinn 430 (2013). For detail review of this machine, please visit: https://www.ellipticalhub.com/schwinn-430-elliptical-trainer
The NEUROMOVE is a neurological re-learning tool, a therapy device, which has been proven to help stroke and other patients recover lost movement. Once a stroke has occurred, the brain loses neurons which cause limb weakness or paralysis. The NeuroMove can train healthy neurons to assume functions lost by damaged brain cells; a concept known as Neuroplasticity. This rehabilitation tool can be used even when there is no muscle movement available. It is sophisticated enough to use in the clinic, yet simple enough for patients to use at home. Thirty minutes a day in four to five months can provide dramatic results.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
2. InWave
Table of Contents
Contact Information / Customer Service / Supplies / Support ........................ 4
About the InWave ........................................................................................... 5
Safety Information .......................................................................................... 6
Sensor and Lead Wire Setup ........................................................................... 9
Programming Instructions ............................................................................... 12
Preprogrammed Modes ................................................................................... 13
Controls........................................................................................................... 15
Operating Instructions..................................................................................... 16
Indications, Contraindications and Warnings………………………..17, 19, 21
Precautions and Adverse Reactions…………………………………..18, 20, 22
Troubleshooting .............................................................................................. 23
Specifications and Accessories ....................................................................... 24
Sensor, Batteries, and Cleaning ...................................................................... 25
Warranty ......................................................................................................... 26
3
3. Zynex Medical
Painezee
Contact Information
Phone0091-9030022402
: 040 1-866-940-7030
- 65522402
CUSTOMER SERVICE
Supplies:
To order more electrodes or other accessories
Technical Support:
Questions or problems with using your device
Device Return:
Order a postage paid return envelope to return your
device at no charge
MAIN OFFICE
Billing Questions:
1-800-495-6670
0091-9030022402
Questions regarding insurance benefits and
covered benefits for Durable Medical Equipment
(DME) or questions about an Explanation of
Benefits form you received in the mail
FAX NUMBER
1-800-495-6695
MAILING ADDRESS
Zynex Medical, Inc.
Plot No: 6, Green Avenues,
9990 Park Meadows DriveNizampet Road,
Opp: Bhavysa Anandham,
Kukatpally, Hyderabad - 500090
Lone Tree, CO 80124-6739
Andhra
USA Pradesh, India
info@zynexmed.com
info@painezee.com
EMAIL
WEBSITE
www.zynexmed.com
www.painezee.com
4
4. About the InWave
The InWave is a multiple-mode stimulator which allows users a choice of
treatment options. The InWave causes muscle contractions which exercise and
strengthen the pelvic floor muscles.
Stress Incontinence Treatment
The output delivers electrical impulses at a frequency of 50 Hz, which produce
smooth, even muscle contractions. This type of stimulation exercises and
strengthens the pelvic floor muscles, which aids in the control of stress
incontinence.
Stimulation can be set to 3 or 5 second duration, with a resting period of 5 or
10 seconds between contractions.
Default treatment time is 15 minutes.
Urge Incontinence Treatment
The output delivers electrical impulses at a frequency of 12.5 Hz, which
produce a series of short, rapid contractions. This type of stimulation aids in
the relaxation of involuntary muscle contractions which cause urge
incontinence.
Stimulation can be set to 6 or 10 second duration, with a resting period of 3 or
10 seconds. Default treatment time is 20 minutes.
Mixed Incontinence Treatment
Mixed treatment modes consist of a 2, 5, or 10 minute stress treatment
followed by a 2, 5, or 10 minute urge treatment. This combination of
stimulation types aids in both stress and urge incontinence in the manners
mentioned above.
Caution: Federal law restricts this device to sale by or on the order of a
licensed healthcare practitioner.
5
5. Safety Information
Equipment Classification
As per the International Electrotechnical Commission standard IEC
60601-1, and the European standard EN 60601-1, Medical Electrical
Equipment, General Requirements for Basic Safety and Essential
Performance, the InWave is classified as follows:
Type BF Equipment
A Type BF piece of equipment is one that provides a particular degree
of protection against electric shock, particularly regarding allowable
leakage current. Type BF applied part is one that is floating above
ground and is isolated from all other parts of the equipment.
Medical Device Directive (MDD) Classification
The InWave is a Class IIa medical device per the European Medical
Device Directive.
Internally Powered Equipment
The InWave is powered by an internal, 9 VDC, MN1604, battery, so
it is classified as Internally Powered Equipment.
Electromagnetic Compatibility
Conforms to IEC 60601-1-2.
Temperature
Operating temperature range: 0° - 40° C (32° - 104° F)
Storage temperature range: -20° - 70° C (-4° - 158° F)
Water Ingress
Ordinary equipment. This device does not have protection against
ingress of water.
Flammable Anesthetics
This device is not suitable for use in the presence of a flammable
anesthetic mixture with air, or in the presence of a flammable
anesthetic mixture with oxygen or nitrous oxide.
6
6. Safety Information
Mode of Operation
This device is suitable for continuous operation.
Symbols
Safety symbols shown on the device above are defined below.
On/Standby. This symbol indicates that the labeled switch
electronically cycles the DC power on and off for part of the
equipment.
General Warning Sign.
Follow warnings stated in the
instruction manual to prevent potential hazards.
Refer to Instruction Manual/Booklet. The operator must read,
understand, and follow all instructions in the accompanying
document including all warnings, cautions, and precautions
before using this medical device.
Type BF Equipment. This symbol indicates that the patient
applied parts (electrodes) are Type BF (floating from ground)
offering the user a specific level of safety.
7
7. Waste Electrical and Electronic Equipment (WEEE). This
product may contain substances known to be hazardous to the
environment or to human health. It should be disposed of
properly (for example, at your local waste collection
administration or recycling plant) and in accordance with local
ordinances.
Service and Calibration
Do not remove the cover. There are no user serviceable parts. Refer all
service to authorized personnel. No modification of the equipment is
allowed.
No preventative inspections are required. Factory testing and calibration
ensure equipment accuracy and response. Contact Zynex Medical for
factory re-calibration if necessary.
8
8. InWave
Sensor and Lead Wire Setup
Step 1
Open the sensor package and remove the sensor. Remove the
electrode wire from the packaging, and unbundle the wire.
Note: Only Zynex Medical sensors are approved for use with the
InWave. P/N 400015 are provided standard.
Step 2
Insert the lead wire pin connectors into the sensor connectors as
shown below.
Sensor
Connections
Lead Wire
9
9. InWave
Electrode and Lead Wire Setup (continued)
Step 3
Insert vaginal sensor as shown below. If needed, a small amount of
water-based lubricant can be applied to the tip of the sensor to aid
in insertion. Initial placement of the vaginal sensor and selection of
the treatment program should be performed under the guidance of a
physician. Note: Overuse of a lubricant can cause lack of
stimulation, and lead to ineffective treatment. In order to avoid
treatment interruption, it may be necessary to empty the bladder and
bowels before starting a treatment session.
See the directions included with the sensor for further information.
Note: The vaginal sensors are for single patient use only.
10
10. InWave
Electrode and Lead Wire Setup (continued)
Step 4
Plug the lead wire into the top of the device.
Step 5
Proceed to page 16 to start treatment or page 12 to program device.
Electrode
Connector
11
11. InWave
Device Programming Instructions
Turn device on by pressing the black On/Standby button
1.
2.
3.
Select the desired Modality by pressing the “STRESS”, “URGE”, or
“MIX” button once.
Press the “+” or “-” portions of the Program button until the arrow on the
LCD is next to the desired program.
Press the Treatment Timer button until the desired treatment time is set on
the screen.
The InWave is now ready to use.
On /
Standby
Button
Modality
Buttons
Treatment
Timer Button
12
12. InWave
Preprogrammed Modes
Stress Incontinence Treatment (50 Hz Frequency, 200 µSecond Pulse Width)
Program
Description
5/10
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 5 second on time, then ramps down to zero over a period of
1 second. The output stays off for the remainder of the 10
second off time. This cycle repeats for the duration of the
treatment time. (Default is 15 minutes.)
3/10
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 3 second on time, then ramps down to zero over a period of
1 second. The output stays off for the remainder of the 10
second off time. This cycle repeats for the duration of the
treatment time. (Default is 15 minutes.)
5/5
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 5 second on time, then ramps down to zero over a period of
1 second. The output stays off for the remainder of the 5
second off time. This cycle repeats for the duration of the
treatment time. (Default is 15 minutes.)
Urge Incontinence Treatment (12.5 Hz Frequency, 600 µSecond Pulse Width)
Program
Description
10/3
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 10 second on time, then ramps down to zero over a period
of 0.5 seconds. The output stays off for the remainder of the 3
second off time. This cycle repeats for the duration of the
treatment time. (Default is 20 minutes.)
6/3
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 6 second on time, then ramps down to zero over a period
of 0.5 seconds. The output stays off for the remainder of the 3
second off time. This cycle repeats for the duration of the
treatment time. (Default is 20 minutes.)
10/10
The output signal ramps up to the level set by the user over a
period of 1 second. The output stays on for the remainder of
the 6 second on time, then ramps down to zero over a period
of 0.5 seconds. The output stays off for the remainder of the 3
second off time. This cycle repeats for the duration of the
treatment time. (Default is 20 minutes.)
13
13. Mixed Incontinence Treatment
Program
Description
10:10
A 10 minute “5/10” Stress program is run, followed by a 10
minute “10/3” Urge program. This cycle repeats for the
duration of the treatment time. Default treatment time is 20
minutes.
5:5
A 5 minute “5/10” Stress program is run, followed by a 5
minute “10/3” Urge program. This cycle repeats for the
duration of the treatment time. Default treatment time is 20
minutes.
2:2
A 2 minute “5/10” Stress program is run, followed by a 2
minute “10/3” Urge program. This cycle repeats for the
duration of the treatment time. Default treatment time is 20
minutes.
The InWave should be used daily for 15 to 20 minutes per session, for 1 to 3 months,
or as directed by a physician.
14
14. InWave
Device Controls
Display
Attach Lead Wire Here
Lead Wire
Connector
Turns Unit On/Off
On/Standby
Button
Cycles Through Programs
Adjusts Treatment Intensity
Program Select Button
Up and Down Button
Unlocks Control Buttons
Unlock Button
STRESS, URGE, MIX
Modality Buttons
Adjusts Treatment Times
Treatment Timer Button
15
15. InWave
Device Operating Instructions
Start Treatment:
Before starting treatment, the sensor must be inserted and the lead wire must
be connected to the InWave. See pages 9-11 for instructions.
1.
Turn the InWave on by pressing the On/Standby button once, and set the
desired program using the Modality and Program buttons.
2.
Increase the stimulation level by pressing the upper portion of the Intensity
button until a strong but comfortable stimulation level is felt.
NOTE: Output increases in 1/2 mA increments up to the 4 mA level, then
increases in increments of 1 mA.
3.
Once the desired level of stimulation is set, the InWave will automatically
shut off after the preset treatment time (shown on the display.) If the
Treatment Timer has been set to, “No Timer,” then the InWave will need
to be shut off manually. Refer to Programming Instructions on page 12 to
adjust the Treatment Timer.
4.
To turn off the InWave manually, press the On/Standby button.
Note: If “Check Connections!” message is displayed on the screen, see “Display Alerts”
below.
During Treatment:
IMPORTANT: Button controls lock after 20 seconds of inactivity. To unlock
button controls, press the Unlock button.
Increase Intensity:
To increase the intensity, press the upper potion of the Intensity button until
the desired level of stimulation is felt.
Decrease Intensity:
To decrease the intensity, press the lower portion of the Intensity button until
the desired level of stimulation is felt.
Display Alerts:
Check Connections: The lead wire and/or the sensor may not be attached
properly. Check all connections and try again (see page 23). If the problem
persists, call Technical Support (see page 4).
Low Battery: Replace the battery immediately.
Locked: The stimulation level and mode cannot be changed until the Unlock
button is pressed.
16
16. InWave
Indications for Use
Stress Incontinence Mode
Please read the InWave User’s Manual before using the InWave pelvic
muscle stimulator.
CAUTION: Federal law restricts this device to sale by or on the order of a
licensed healthcare practitioner. This device should only be used under medical
supervision for adjunctive therapy for the treatment of medical diseases and
conditions.
Indications
The Zynex Medical InWave is intended to provide electrical stimulation
and neuromuscular re-education for the purpose of rehabilitation of weak
pelvic floor muscles for the treatment of stress, urge, and mixed urinary
incontinence in women.
Contraindications
This InWave should not be used in the presence of the following:
-Where there is a tendency to hemorrhage following acute trauma or
fracture.
-Following recent surgical procedures when muscle contraction may
disrupt the healing process.
-Over the menstruating or pregnant uterus.
-Over areas of the skin which lack normal sensation.
-Irregular menstrual cycles.
-Urinary or vaginal infection.
-History of urinary retention or current symptoms.
Warnings
The long-term effects of chronic electrical stimulation are unknown.
Safety has not been established for the use of the InWave during
pregnancy.
The device is capable of generating currents and voltages in excess of 10
mA RMS and 10 V RMS, respectively. A yellow LED indicator is
provided next to the lead wire connector to show that the unit is delivering
energy for any non-zero value of stimulation output (0.5 to 80 mA).
Discontinue use of this device in the event of pain or bleeding.
Do not use this device in water.
Do not insert the lead wires into a mains power supply.
17
17. InWave
Precautions and Adverse Reactions
Stress Incontinence Mode
Precautions
Stimulation settings should be based on the guidance of the prescribing
practitioner.
This device should be kept out of the reach of children.
This device should only be used with the leads and vaginal sensor
recommended for use by the manufacturer.
This device should not be used while driving, operating machinery, or
during any activity in which involuntary muscle contractions may put the
user at risk of injury.
Caution should be exercised when this device is used by patients with
pacemakers and heart rhythm problems.
Do not use this device while under the influence of drugs or alcohol.
Do not insert or remove the vaginal sensor while the device is ON.
Do not use this device while in the close proximity of wireless devices.
Use this device only as directed.
Do not immerse the unit in water or any other liquid.
The vaginal sensor should not remain inserted in the vagina when the unit
is not in use.
This device should not be used while sleeping or when anything else is in
the vagina, such as a diaphragm or tampon.
Adverse Reactions
Skin irritation and electrode burns are potential adverse reactions.
Safety References
Zynex Medical, Inc. is only responsible for the safety, reliability and function
of the device when repairs and adjustments have been made by persons
authorized by Zynex Medical, Inc., and the device is used in accordance with
the user’s manual. Repairs and technical safety tests shall only be performed
by authorized personnel.
18
18. InWave
Indications for Use
Urge Incontinence Mode
Please read the InWave User’s Manual before using the InWave pelvic
muscle stimulator.
CAUTION: Federal law restricts this device to sale by or on the order of a
licensed healthcare practitioner. This device should only be used under medical
supervision for adjunctive therapy for the treatment of medical diseases and
conditions.
Indications
The Zynex Medical InWave is intended to provide electrical stimulation
and neuromuscular re-education for the purpose of rehabilitation of weak
pelvic floor muscles for the treatment of stress, urge, and mixed urinary
incontinence in women.
Contraindications
This InWave should not be used in the presence of the following:
-Where there is a tendency to hemorrhage following acute trauma or
fracture.
-Following recent surgical procedures when muscle contraction may
disrupt the healing process.
-Over the menstruating or pregnant uterus.
-Over areas of the skin which lack normal sensation.
-Irregular menstrual cycles.
-Urinary or vaginal infection.
-History of urinary retention or current symptoms.
Warnings
The long-term effects of chronic electrical stimulation are unknown.
Safety has not been established for the use of the InWave during
pregnancy.
The device is capable of generating currents and voltages in excess of 10
mA RMS and 10 V RMS, respectively. A yellow LED indicator is
provided next to the lead wire connector to show that the unit is delivering
energy for any non-zero value of stimulation output (0.5 to 80 mA).
Discontinue use of this device in the event of pain or bleeding.
Do not use this device in water.
Do not insert the lead wires into a mains power supply.
19
19. InWave
Precautions and Adverse Reactions
Urge Incontinence Mode
Precautions
Stimulation settings should be based on the guidance of the prescribing
practitioner.
This device should be kept out of the reach of children.
This device should only be used with the leads and vaginal sensor
recommended for use by the manufacturer.
This device should not be used while driving, operating machinery, or
during any activity in which involuntary muscle contractions may put the
user at risk of injury.
Caution should be exercised when this device is used by patients with
pacemakers and heart rhythm problems.
Do not use this device while under the influence of drugs or alcohol.
Do not insert or remove the vaginal sensor while the device is ON.
Do not use this device while in the close proximity of wireless devices.
Use this device only as directed.
Do not immerse the unit in water or any other liquid.
The vaginal sensor should not remain inserted in the vagina when the unit
is not in use.
This device should not be used while sleeping or when anything else is in
the vagina, such as a diaphragm or tampon.
Adverse Reactions
Skin irritation and electrode burns are potential adverse reactions.
Safety References
Zynex Medical, Inc. is only responsible for the safety, reliability and function
of the device when repairs and adjustments have been made by persons
authorized by Zynex Medical, Inc., and the device is used in accordance with
the user’s manual. Repairs and technical safety tests shall only be performed
by authorized personnel.
20
20. InWave
Indications for Use
Mixed Incontinence Mode
Please read the InWave User’s Manual before using the InWave pelvic
muscle stimulator.
CAUTION: Federal law restricts this device to sale by or on the order of a
licensed healthcare practitioner. This device should only be used under medical
supervision for adjunctive therapy for the treatment of medical diseases and
conditions.
Indications
The Zynex Medical InWave is intended to provide electrical stimulation
and neuromuscular re-education for the purpose of rehabilitation of weak
pelvic floor muscles for the treatment of stress, urge, and mixed urinary
incontinence in women.
Contraindications
This InWave should not be used in the presence of the following:
-Where there is a tendency to hemorrhage following acute trauma or
fracture.
-Following recent surgical procedures when muscle contraction may
disrupt the healing process.
-Over the menstruating or pregnant uterus.
-Over areas of the skin which lack normal sensation.
-Irregular menstrual cycles.
-Urinary or vaginal infection.
-History of urinary retention or current symptoms.
Warnings
The long-term effects of chronic electrical stimulation are unknown.
Safety has not been established for the use of the InWave during
pregnancy.
The device is capable of generating currents and voltages in excess of 10
mA RMS and 10 V RMS, respectively. A yellow LED indicator is
provided next to the lead wire connector to show that the unit is delivering
energy for any non-zero value of stimulation output (0.5 to 80 mA).
Discontinue use of this device in the event of pain or bleeding.
Do not use this device in water.
Do not insert the lead wires into a mains power supply.
21
21. InWave
Precautions and Adverse Reactions
Mixed Incontinence Mode
Precautions
Stimulation settings should be based on the guidance of the prescribing
practitioner.
This device should be kept out of the reach of children.
This device should only be used with the leads and vaginal sensor
recommended for use by the manufacturer.
This device should not be used while driving, operating machinery, or
during any activity in which involuntary muscle contractions may put the
user at risk of injury.
Caution should be exercised when this device is used by patients with
pacemakers and heart rhythm problems.
Do not use this device while under the influence of drugs or alcohol.
Do not insert or remove the vaginal sensor while the device is ON.
Do not use this device while in the close proximity of wireless devices.
Use this device only as directed.
Do not immerse the unit in water or any other liquid.
The vaginal sensor should not remain inserted in the vagina when the unit
is not in use.
This device should not be used while sleeping or when anything else is in
the vagina, such as a diaphragm or tampon.
Adverse Reactions
Skin irritation and electrode burns are potential adverse reactions.
Safety References
Zynex Medical, Inc. is only responsible for the safety, reliability and function
of the device when repairs and adjustments have been made by persons
authorized by Zynex Medical, Inc., and the device is used in accordance with
the user’s manual. Repairs and technical safety tests shall only be performed
by authorized personnel.
22
22. Troubleshooting
Problem
Solution
Unit stays on even
after treatment ends.
Hold Off button down for 2 seconds to shut unit off.
Otherwise unit will shut off automatically after 5
minutes of no stimulation. Alternatively you can start
a new treatment session after the last one ends.
Cannot increase level
from its current setting.
Press and release Unlock button to unlock this safety
feature. Then increase stimulation to the desired level
of intensity. Intensity level is always locked after 20
seconds of key press inactivity.
Display shows “Check Check to see that the sensor is properly inserted.
Connections”
(Remove and re-insert the sensor if necessary to
(Electrode alarm).
establish a better electrical contact.) Verify that the
sensor is correctly connected to the lead wire and that
the lead wire is correctly connected to the InWave.
Connect the bare metal pins of the lead wire together
to short-circuit the output. If the electrode alarm ceases
the problem is with the sensor connection integrity.
Removing and re-inserting the sensor may establish a
better electrical contact.
23
23. InWave
Specifications and Accessories
Stress Incontinence Mode
Amplitude:
Frequency:
Pulse Width:
Stress Modes:
On Time:
Off Time:
Ramp Up Time:
Ramp Down Time:
Waveforms:
0-80 mA
50 Hz
200 µseconds
5/10, 3/10, 5/5
3 or 5 seconds
5 or 10 seconds
1 second
1 second
Symmetrical biphasic
Urge Incontinence Mode
Amplitude:
Frequency:
Pulse Width:
Urge Modes:
On Time:
Off Time:
Ramp Up Time:
Ramp Down Time:
Waveform:
0-80 mA
12.5 Hz
600 µseconds
10/3, 6/3, 10/10
6 or 10 seconds
3 or 10 seconds
1 second
0.5 seconds
Symmetrical biphasic
Mixed Incontinence Mode
Amplitude:
Frequency:
Pulse Width:
Mix Modes:
On-Time:
Off-Time:
Ramp Up:
Ramp Down:
Waveforms:
0-80 mA
12.5 Hz and 50 Hz
200 µseconds and 600 µseconds
10:10, 5:5, 2:2
3, 5, 6, or 10 seconds
3, 5, or 10 seconds
1 second
0.5 or 1 second
Symmetrical biphasic
Other Specifications
Treatment timer:
5 to 25 minutes, in 5 minute increments.
Compliance meter:
Records total usage time in minutes and number of times
used.
Dimensions:
2.9 x 4.6 x 1.0 in.
Weight:
5.8 oz. including battery
Warranty:
5 year manufacturer’s warranty on materials and
workmanship. Accessories excluded.
Accessories
Lead wire:
104204, lead wire, gray.
Sensor:
400015, vaginal sensor.
Battery:
130010, battery, 9 Volt, alkaline, MN1604.
24
24. InWave
Sensor, Batteries, and Cleaning
Sensor Use
The InWave is intended to be used with a re-usable vaginal sensor. Before and
after each use, clean the sensor with mild soap and water, and dry the sensor.
Store the sensor in a safe location when not in use.
Follow directions of the prescribing physician.
Note: The vaginal sensors are for single patient use only.
Battery Power
One 9 Volt alkaline battery is used to power the InWave. The battery
compartment on the back of the device opens by sliding the cover downwards.
Rechargeable batteries are not recommended since they have only a short
usage time and cannot be charged while in the InWave.
Battery replacement is indicated by the battery icon in the display. Replace
with a new 9 Volt alkaline battery.
The InWave operates normally even if the 9 Volt battery is inserted with
reverse polarity.
Please dispose of used batteries properly.
Device Cleaning
The InWave case and display window can be cleaned by lightly applying mild
soap to a damp soft cloth or paper towel and using it to wipe the surfaces clean.
Allow the unit to dry thoroughly before using. Do not spray cleaning solutions
directly onto the unit, or immerse it in water or other liquids.
25
25. InWave
Warranty Information
The InWave device is warranted to be free from defects in material,
workmanship, and structural integrity when subjected to normal domestic use
and service for five years after the original purchase.
During that time, Zynex Medical, Inc will repair or replace, at its sole
discretion, the InWave device that has been used in a standard manner. This
warranty does not cover misuse or use contrary to the operating instructions
supplied.
Warranty obligations are limited to replacement or repair of defective parts and
components, at the option of Zynex Medical, Inc. This Warranty is only valid
for the original purchaser of this product and will not be honored if the product
ownership is transferred or is resold.
To obtain warranty service, please contact Technical Support at the number
listed on page 4 of this manual.
26